CPL @1097 (93.1%) on 19-jan-2018 [ "_ is an oral medication" "different dose of _" "drug , called _" "therapeutic/adverse effects of _" "_ is a newer drug" ] using ambrisentan
SEAL @238 (87.5%) on 18-apr-2011 [ 123 ] using ambrisentan
CPL @1098 (97.3%) on 21-jan-2018 [ "dose of _" "treatment with _" "drug application for _" "side effects of _" "patient is receiving _" "drugs , including _" "_ has not been studied in" "medications such as _" "first dose of _" "you are taking _" "_ is excreted in" "patient treated with _" "tolerability of _" "patients receiving _" "people treated with _" "possible side effects of _" "dosage of _" "higher dose of _" "safety profile of _" "women treated with _" "DD-mg dose of _" "new drug application for _" "drug interactions with _" "patients treated with _" "clinical development of _" "drug called _" "higher dosage of _" "doses of _" "Common side effects of _" "therapy with _" ] using ambrisentan
relations
NELL has only weak evidence for items listed in grey